Company intelligence / Profile preview

Sichuan Prite Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Sichuan Prite Pharmaceutical develops both small molecule drugs and gene therapies. Its most advanced product is dexmedetomidine hydrochloride for sedation, which has achieved approval status. Other pipeline assets include an investigational ketamine enantiomer for depressive disorders at Phase 1, a mucous secretion modulator at IND stage, and a discovery-stage respiratory disease program targeting CD51. The company has conducted multiple clinical trials with several programs progressing through early to mid-stage development.

Therapeutic areas: PulmonologyPsychiatryNeurology
Modalities: Small moleculeGene therapy
Industry: Biotech

Drug pipeline

2 assets

PRT-064040

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sichuan Prite Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sichuan Prite Pharmaceutical.

Explore the full profile